398 related articles for article (PubMed ID: 29695817)
21. Endocannabinoid degradation inhibitors ameliorate neuronal and synaptic alterations following traumatic brain injury.
Fucich EA; Stielper ZF; Cancienne HL; Edwards S; Gilpin NW; Molina PE; Middleton JW
J Neurophysiol; 2020 Feb; 123(2):707-717. PubMed ID: 31913777
[TBL] [Abstract][Full Text] [Related]
22. Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety.
Bedse G; Hartley ND; Neale E; Gaulden AD; Patrick TA; Kingsley PJ; Uddin MJ; Plath N; Marnett LJ; Patel S
Biol Psychiatry; 2017 Oct; 82(7):488-499. PubMed ID: 28438413
[TBL] [Abstract][Full Text] [Related]
23. Dual pharmacological inhibitor of endocannabinoid degrading enzymes reduces depressive-like behavior in female rats.
Dong B; Shilpa BM; Shah R; Goyal A; Xie S; Bakalian MJ; Suckow RF; Cooper TB; Mann JJ; Arango V; Vinod KY
J Psychiatr Res; 2020 Jan; 120():103-112. PubMed ID: 31654971
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Monoacylglycerol Lipase Reduces the Reinstatement of Methamphetamine-Seeking and Anxiety-Like Behaviors in Methamphetamine Self-Administered Rats.
Nawata Y; Yamaguchi T; Fukumori R; Yamamoto T
Int J Neuropsychopharmacol; 2019 Feb; 22(2):165-172. PubMed ID: 30481332
[TBL] [Abstract][Full Text] [Related]
25. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.
Ramesh D; Ross GR; Schlosburg JE; Owens RA; Abdullah RA; Kinsey SG; Long JZ; Nomura DK; Sim-Selley LJ; Cravatt BF; Akbarali HI; Lichtman AH
J Pharmacol Exp Ther; 2011 Oct; 339(1):173-85. PubMed ID: 21719468
[TBL] [Abstract][Full Text] [Related]
26. The temporal dynamics of the effects of monoacylglycerol lipase blockade on locomotion, anxiety, and body temperature.
Aliczki M; Balogh Z; Tulogdi A; Haller J
Behav Pharmacol; 2012 Aug; 23(4):348-57. PubMed ID: 22750842
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice.
Gamage TF; Ignatowska-Jankowska BM; Muldoon PP; Cravatt BF; Damaj MI; Lichtman AH
Drug Alcohol Depend; 2015 Jan; 146():7-16. PubMed ID: 25479915
[TBL] [Abstract][Full Text] [Related]
28. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.
Anderson WB; Gould MJ; Torres RD; Mitchell VA; Vaughan CW
Neuropharmacology; 2014 Jun; 81():224-30. PubMed ID: 24384256
[TBL] [Abstract][Full Text] [Related]
29. Endocannabinoid Hydrolase Inhibitors: Potential Novel Anxiolytic Drugs.
Zhao H; Liu Y; Cai N; Liao X; Tang L; Wang Y
Drug Des Devel Ther; 2024; 18():2143-2167. PubMed ID: 38882045
[TBL] [Abstract][Full Text] [Related]
30. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
31. Potential Therapeutic Value of a Novel FAAH Inhibitor for the Treatment of Anxiety.
Marco EM; Rapino C; Caprioli A; Borsini F; Laviola G; Maccarrone M
PLoS One; 2015; 10(9):e0137034. PubMed ID: 26360704
[TBL] [Abstract][Full Text] [Related]
32. Early suppression of the endocannabinoid degrading enzymes FAAH and MAGL alters locomotor development in zebrafish.
Sufian MS; Amin MR; Ali DW
J Exp Biol; 2021 Aug; 224(16):. PubMed ID: 34435626
[TBL] [Abstract][Full Text] [Related]
33. Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal grey.
Lau BK; Drew GM; Mitchell VA; Vaughan CW
Br J Pharmacol; 2014 Dec; 171(23):5225-36. PubMed ID: 25041240
[TBL] [Abstract][Full Text] [Related]
34. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling.
Pan B; Wang W; Long JZ; Sun D; Hillard CJ; Cravatt BF; Liu QS
J Pharmacol Exp Ther; 2009 Nov; 331(2):591-7. PubMed ID: 19666749
[TBL] [Abstract][Full Text] [Related]
35. Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
Korhonen J; Kuusisto A; van Bruchem J; Patel JZ; Laitinen T; Navia-Paldanius D; Laitinen JT; Savinainen JR; Parkkari T; Nevalainen TJ
Bioorg Med Chem; 2014 Dec; 22(23):6694-6705. PubMed ID: 25282655
[TBL] [Abstract][Full Text] [Related]
36. Organophosphate agents induce plasma hypertriglyceridemia in mouse via single or dual inhibition of the endocannabinoid hydrolyzing enzyme(s).
Suzuki H; Ito Y; Noro Y; Koketsu M; Kamijima M; Tomizawa M
Toxicol Lett; 2014 Feb; 225(1):153-7. PubMed ID: 24361246
[TBL] [Abstract][Full Text] [Related]
37. Phenolic compounds from nutmeg (Myristica fragrans Houtt.) inhibit the endocannabinoid-modulating enzyme fatty acid amide hydrolase.
El-Alfy AT; Abourashed EA; Patel C; Mazhari N; An H; Jeon A
J Pharm Pharmacol; 2019 Dec; 71(12):1879-1889. PubMed ID: 31595522
[TBL] [Abstract][Full Text] [Related]
38. Contrasting effects of selective MAGL and FAAH inhibition on dopamine depletion and GDNF expression in a chronic MPTP mouse model of Parkinson's disease.
Pasquarelli N; Porazik C; Bayer H; Buck E; Schildknecht S; Weydt P; Witting A; Ferger B
Neurochem Int; 2017 Nov; 110():14-24. PubMed ID: 28826718
[TBL] [Abstract][Full Text] [Related]
39. Enhanced anandamide signaling reduces flight behavior elicited by an approaching robo-beetle.
Heinz DE; Genewsky A; Wotjak CT
Neuropharmacology; 2017 Nov; 126():233-241. PubMed ID: 28890367
[TBL] [Abstract][Full Text] [Related]
40. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.
Ren SY; Wang ZZ; Zhang Y; Chen NH
Acta Pharmacol Sin; 2020 Oct; 41(10):1263-1271. PubMed ID: 32203086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
